Sinopep-Allsino Biopharmaceutical Co., Ltd.

The premiere gathering of heavy hitters within the global bio/pharmaceutical industry. The 2025 DCAT (Drug, Chemical & Associated Technologies Association) saw Thomas Tong (Chairman) and Darwin Li (Sr. VP) leading the BD team to participate in this grand event. Throughout the sessions, Sinopep-Allsino Biopharmaceutical Co., Ltd. met and discussed the collaborations with the global business partners and customers, paving the way for continued success. In September 2024, Sinopep successfully passed the FDA’s unnoticed cGMP inspection, which earned the customers’ recognition for the excellent quality operations. Sinopep remains committed to its platform strategy and continuously enhancing the professionalism to provide the best possible values to its customers, partners and the society. If we didn’t connect during DCAT, feel free to reach out to: Sinopep- API Manufacturer(Semaglutide/Tirzepatide) Ella _Sinopep Annie Chen #DCATWeek #Sinopep #PeptideManufacturing #CDMO #CRDMO #Biotech #Pharma #LifeScience #DrugDevelopment

We're looking forward to connecting at DCAT week! Join us to discuss innovative collaborations and discover new opportunities. It's not too late to register a meeting with us. For more information, contact ella@sinopep.com. See you there!

We're excited to meet with you during DCAT week! At Sinopep-Allsino Biopharmaceutical Co., Ltd., our commitment lies in establishing a strategic partnership built on trust, providing you with the highest quality products and services. #Sinopep #Biopharmaceutical #Biotech #Pharma #CDMO #CRDMO #Peptide #Oligonucleotide #Smallmolecules #API #Manufacturing

We're #hiring a BD associate specifically for America. Apply today or share this post in your network! #sinopep #oligonucleotide #peptide #smallmolecules #CDMO #CRO #CRDMO #biotech #pharmaceutical #APImanufacturer

🎉South Korean MFDS GMP certificate for Semaglutide and Fulvestrant

👏 Come meet this year at these events👏

📢 Recently, Sinopep-Allsino Biopharmaceutical Co., Ltd. Lianyungang factory has obtained the GMP certificate issued by the Korean MFDS(Ministry of Food and Drug Safety). The factory passed the on-site inspection for the APIs, Semaglutide and Fulvestrant with zero defects, laying a solid foundation for the registration and compliance of these products in PIC/S member countries. This achievement will accelerate the company's overseas market development and brand promotion for its APIs. 💡 Semaglutide is a novel long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes in adults, as well as for chronic weight management (for individuals who are overweight and have at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol). It offers significant advantages including long-term blood sugar control, notable weight loss effects, cardiovascular protection, good safety profile, flexible dosage forms, and ease of use. Semaglutide has been approved for use in over 50 countries and regions. It is the sixth GLP-1RA drug to be approved and the third long-acting hypoglycemic agent administered once weekly. 📆 In June 2024, its indication for weight loss was approved in China, allowing it to be used for long-term weight management in adult patients based on controlled diet and increased physical activity. 💡Fulvestrant is a novel estrogen receptor antagonist used for the treatment of metastatic advanced breast cancer in postmenopausal women whose disease has progressed after ineffective anti-estrogen therapy or who are hormone receptor (ER) positive. This drug competitively binds to the estrogen receptor with an affinity similar to estradiol; it also blocks the receptor, inhibits estrogen binding, induces morphological changes in the receptor, reduces ER concentration, and thereby impairs tumor cells. According to relevant studies, this drug can significantly improve the treatment efficacy of malignant tumors, reduce drug resistance, and prolong patient survival when used in combination therapy. The successful inspection by the regulatory authorities of the PIC/S member countries highlights the company's exceptional level of international registration. This achievement is a testament to the rigorous quality control system in place and the relentless efforts of the quality and production teams. Looking ahead, this accomplishment not only enhances the overall competitiveness of the products but also opens new avenues for expanding into the South Korean and other international markets, contributing to the company's pursuit of high-quality development. For more information please contact: Ella Guo Email: ella@sinopep.com Linkedin: Ella _Sinopep or Sinopep- Semaglutide/Tirzepatide API Manufacturer #SINOPEP #Biotech #Pharmaceutical #Peptide #SmallMolecules #CRDMO #CDMO #CRO #MFDS #cGMP #Semaglutide #Fulvestrant #Manufacturing

📢 We're excited to announce that Sinopep-Allsino Biopharmaceutical Co., Ltd. will be attending the following events this year 📍DCAT week 📅 March 17th-20th, New York, USA 📍BIO CHINA 📅 March 13th-15th, Suzhou, China 📌 Booth: SD3-042 📍CPHI Americas 📅 May 20th-22nd, Philadelphia, USA 📌Booth: 1119 📍TIDES USA 📅 May 19th-22nd, San Diego, USA 📍API China 📅 May 21st-23rd, Guangzhou, China 📌 Booth: 11.2M35 📍CPHI Shanghai 📅 June 24th-26th, Shanghai, China 📌Booth: E2A416 📍CPHI Korea 📅 August 26th-28th, Seoul, South Korea 📌Booth: F28 📍CPHI Frankfurt 📅 October 28th-30th, Frankfurt, Germany 📌Booth: 11.1C33 📍TIDES EU 📅 November 11th-13th, Basel, Switzerland 📍CPHI India 📅 November 25th-27th, Delhi, India You can meet us at our booths, arrange a meeting through Linkedin, or email us at ella@sinopep.com #Sinopep #CDMO #CRO #CRDMO #Peptide #Oligonucleotide #SmallMolecules #Biopharmaceutical #Pharma #Biotech #Manufacturing #LargeBatchSize

📆 JAN 2025 Sinopep-Allsino Biopharmaceutical Co., Ltd. Our Lianyungang factory received the Establishment Inspection Report (EIR) issued by the U.S. Food and Drug Administration (FDA）regarding the September 2024 inspection. The report indicated that the production facility located at 28 Linpu Road, Economic and Technological Development Zone, Lianyungang City, Jiangsu Province, has passed the cGMP on-site inspection. 📆 SEPT 2024 Last year, two inspectors from the U.S. FDA conducted a thorough five-day on-site inspection, covering various peptides and small molecule chemical drugs across several workshops. The scope of this inspection included evaluating the: 🧬 Quality management systems 🧬 Equipment and Facilities systems 🧬 Production systems 🧬 Packaging and Labeling systems 🧬 Material management systems 🧬 Laboratory control systems Passing the challenging U.S. FDA cGMP inspection demonstrates that the company's quality management system and production environment is up to FDA's standard. This achievement provides a solid foundation for our international market development and enhances our overall competitiveness. Our quality system is continuously improving and aligning with international standards. Looking ahead, we will continue to build production bases for raw materials and formulations meet both Chinese and international standards. We will keep updating our quality, innovating our technology, and reforming our management to further support the internationalization of our products. For more information please contact: Ella Guo Email: ella@sinopep.com Linkedin: Ella _Sinopep #Sinopep #Pharmaceutical #Biotech #Peptide #SmallMolecules #CRDMO #CDMO #CRO #FDA #cGMP #EIR

We're #hiring a new Head of Oligonucleotide R&D in San Diego, California. Apply today or share this post with your network.